# Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

> **NCT01417000** · PHASE2 · COMPLETED · sponsor: **Aduro Biotech, Inc.** · enrollment: 93 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** GVAX Pancreas
- **BIOLOGICAL:** CRS-207
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01417000
- **Lead sponsor:** Aduro Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-21
- **Primary completion:** 2016-10
- **Final completion:** 2017-02-10
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2018-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01417000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01417000, "Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01417000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*